MaRS Innovation staff and WaveCheck Campaign Co-directors Dr. Fazila Seker and Elizabeth Monier-Williams spoke with the CBC's Colleen Ross about the process of crowdfunding WaveCheck's partner-based clinical studies on "The World This Weekend."
The radio segment, called "Crowdfunding Science," aired on January 25, 2014 and discussed the lack of funding researchers have access to for commercialization, making it harder to advance research that could be helping people in a variety of industries.
To listen to the full interview, click here.
WaveCheck's crowdfunding campaign is an example of ...
MI portfolio company actively seeking additional products for licensing and development
TORONTO and SAN DIEGO, Jan. 9, 2014 — A unique collaboration of life science leaders, including the Fight Against Cancer Innovation Trust, MaRS Innovation Ventures Trust and MaRS Phase II Investment Trust, have formed Triphase Accelerator Corporation, an oncology development accelerator.
Triphase Accelerator's announcement was covered in Yonge Street Media, Bloomburg Businessweek and Global University Venturing.
Formed in 2010, Triphase Accelerator Corporation is a cancer-focused biotechnology development company that aims to reduce the ...
Over 340 people worldwide have joined WaveCheck's Indiegogo crowdfunding campaign to fund a breakthrough clinical technique for breast cancer that promises to revolutionize the way chemotherapy is monitored.
"Breast Cancer Awareness Month’s positivity makes it easy to overlook the fact that 60 to 70 per cent of chemotherapy treatments fail,” says Dr. Gregory Czarnota, chief of Radiation Oncology at Sunnybrook Health Sciences Centre and co-inventor of WaveCheck with Professor Michael C. Kolios of Ryerson University. “WaveCheck’s technology can tell people with breast ...
Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. This post coincided with World Cancer Day.
What if you could use a cancer tumour’s proteomic profile to make it easier to target and destroy?
Targeting specific proteins on the surface of individual tumours—or, more precisely, targeting a cell receptor that naturally allows substances to pass into a cell—would allow clinicians to more effectively deliver ...
MaRS Innovation's (MI) projects and partnerships earned three separate article mentions in the December 2012 issue of Biotechnology Focus, including:
MI and UHN's partnership with Stem Cell Therapeutics was covered in the magazine's Dealmakers subsection. Read the write-up on the Biotechnology Focus website.
Cellax, a licensable technology that may produce a nanotechonology-based cancer drug, was highlighted in the magazine's Business Corner section (read the write-up). Cellax is a joint project between MI and the Ontario Institute for Cancer Research.
MaRS Innovation's ...
Stem Cell Therapeutics Corp. (TSX VENTURE:SSS), a life sciences company developing stem cell-related technologies, today announced the signing of an agreement with University Health Network (UHN), through its commercialization agent MaRS Innovation (MI), both of Toronto.
The agreement provides Stem Cell Therapeutics ("SCT") with an option to an exclusive world-wide license to an innovative cancer stem cell program.
This agreement produced a license for a UHN technology on April 17, 2013.
The Los Angeles Times featured Dr. Gregory Czarnota's research in their Science Now section on July 10, 2012, which reports on discoveries from the world of science and medicine (update: the article is no longer available online).
Czarnota, a researcher at the Sunnybrook Health Sciences Centre, is working with MaRS Innovation to license his patented technology: radiosensitization of tumour cells using a combination of microbubbles and targeted, high-intensity, focused ultrasound. (more…)